CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, started facility expansions as more customers approach late-stage clinical development and commercialization.

Through early 2018, research and development laboratory as well as production and warehouse space will be added to its German headquarters in Freiburg. Consequently, new positions in research and development as well as quality control and production will be filled. The upgrade also introduces state-of-the-art, large scale, filling capacities for recombinant protein products in the existing GMP facilities.

The expansion is the result of robust, sustainable and profitable growth which the company has experienced over the previous years. These advancements are reflective of the rapidly expanding cell and gene therapy space as promising therapies approach market authorization and commercialization. The experienced industry growth and strong forecasts in cell and gene therapy lead to an increased demand in GMP-grade raw materials for production.

“The investment we are making is a very positive sign for the gene and cell therapy space and the future of CellGenix. It will allow us to fulfill the increasing demand for GMP-grade cytokines and serum-free media. It also shows the importance of high quality GMP reagents for safe, reliable and successful cell and gene therapy manufacturing.” says Prof. Dr. Felicia Rosenthal, CEO of CellGenix.

Frank Hecht, Vice President Marketing & Sales at CellGenix, adds: “With this expansion we strengthen our position as a leading partner for all companies active in the manufacturing of cell and gene therapies and we are ready to grow with them into their commercial phase.”